Ribociclib/Letrozole Combination an Important Advance in HR+ Metastatic Breast Cancer
October 10th 2016Findings of a recent multicenter randomized trial<sup> </sup>showed postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer (MBC) had significant slowing of disease progression with the addition of the investigational cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib to endocrine therapy.
Read More
Anthracycline-Based Chemotherapy Produces Significant Survival Benefit in Sarcoma
October 10th 2016A technically negative trial in high-risk adult soft tissue sarcoma nonetheless produced a significant survival benefit for anthracycline-based neoadjuvant chemotherapy, according to a study presented at the 2016 ESMO Congress.
Read More
PFS Three Times Longer With Ceritinib Than With Chemotherapy in ALK+ NSCLC
October 10th 2016Progression-free survival (PFS) was more than 3 times longer with ceritinib (Zykadia) than with chemotherapy, the current second-line standard, in patients with advanced <em>ALK</em>-positive non–small cell lung cancer (NSCLC) who progressed after first-line crizotinib.
Read More
Significant Disparities in Access to Novel Agents For Patients With Melanoma
October 9th 2016Lidija Kandolf Sekulovic, MD, PhD, associate professor of Dermatology, Military Medical Academy in Belgrade, Serbia, discusses a recently published survey during an interview at the 2016 ESMO Congress. The survey found that several thousand patients with metastatic melanoma in Europe do not have access to new, life-saving agents in this field.
Watch
The Efficacy of Dabrafenib in Pediatric Patients With BRAF V600-Mutant Low-Grade Gliomas
October 9th 2016Mark Kieran, MD, PhD, director, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute, discusses the results of a study that evaluated dabrafenib as a treatment for pediatric patients with BRAF V600-mutant relapsed or refractory low-grade gliomas during an interview at the 2016 ESMO Congress.
Watch
Pembrolizumab Data Will Change Management of NSCLC
October 9th 2016Single-agent pembrolizumab (Keytruda) reduced the risk of death by 40% and improved progression-free survival (PFS) by 4.3 months compared with doublet chemotherapy for untreated patients with advanced non–small cell lung cancer (NSCLC) with PD-L1 expression on ≥50% of cells, according to findings from the phase III KEYNOTE-024 trial.
Read More
Regorafenib Has Potential to Become Second-Line Standard of Care in HCC
October 8th 2016The oral multikinase inhibitor regorafenib (Stivarga) has the potential to become the standard of care as second-line treatment in patients with previously treated hepatocellular carcinoma (HCC) who are unsuitable for loco-regional therapy and have progressed on sorafenib.
Read More
Results of the MONALEESA-2 Study in Advanced Breast Cancer
October 8th 2016Gabriel Hortobagyi, MD, professor of Medicine, University of Texas, MD Anderson Cancer Center, discusses the major findings of the MONALEESA-2 study in advanced breast cancer, during an interview at the 2016 ESMO Congress.
Watch
Niraparib is a Breakthrough for Patients With Ovarian Cancer, Expert Says
October 8th 2016Maintenance therapy with the PARP1/2 inhibitor niraparib reduced the risk of progression or death by 73% compared with placebo for patients with germline <em>BRCA</em>-positive platinum-sensitive, recurrent ovarian cancer, according to findings from the phase III NOVA trial.
Read More
Thousands of Metastatic Melanoma Patients in Europe Without Access to Novel Agents
October 8th 2016Over one-fourth of patients with metastatic melanoma in Europe do not have access to groundbreaking therapies that could extend their lives, according to a survey presented at the 2016 ESMO Congress.
Read More
Factors Associated With Discordance in Mutation Status in Metastatic CRC
October 8th 2016Mikhail Fedyanin, MD, medical oncologist, Russian Academy of Medical Sciences, Moscow, discusses some of the factors associated with discordance in mutation status in metastatic colorectal cancer during the 2016 ESMO Congress.
Watch
No Benefit from Combined Irradiation in Intermediate-Risk Prostate Cancer
October 7th 2016The addition of external-beam radiotherapy (EBRT) to interstitial brachytherapy failed to reduce prostate cancer progression compared to brachytherapy alone in men with intermediate-risk disease, interim data from a randomized trial showed.
Read More
Study Results Show Chemoradiation Significantly Improves PFS in Follicular Lymphoma
October 1st 2016According to findings from a multicenter randomized trial, chemoradiation for early-stage, low-grade follicular lymphoma led to significant improvement in progression-free survival (PFS) compared with involved-field radiotherapy alone (IFRT).
Read More
The Role of Immunotherapy in Breast Cancer
September 25th 2016Hope Rugo, MD, clinical professor, department of medicine, and director of Breast Oncology Clinical Trials Program, at University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the role of immunotherapy in breast cancer.
Watch
Questions That Remain Regarding Combination, Sequencing With PARP Inhibitors
September 25th 2016Patricia LoRusso, DO, PhD, professor of medicine and associate director of Innovative Medicine at Yale Cancer Center, discusses the key questions that still remain regarding combination and sequencing with PARP inhibitors.
Watch
Expert Explores the Next Frontier in Endocrine Therapy for Breast Cancer
September 25th 2016Endocrine therapy has come a long way as a treatment for breast cancer since tamoxifen ruled the adjuvant therapy landscape in 1989, but much remains unknown about newer therapies and combating endocrine resistant mutations<br />
Read More
Friedewald Explains Benefits, Limitations of Tomosynthesis for Breast Cancer Screening
September 24th 2016Radiologists have been challenged by the ever-changing recommendations of when breast cancer screening should begin and the frequency of screening, says Sarah M. Friedewald, MD. The controversy surrounding screening recommendations can be a distraction to the implementation of new technologies, such as tomosynthesis.
Read More
Why Nomograms Provide Optimal Risk Assessment of Recurrent DCIS
September 23rd 2016Kimberly J. Van Zee, MS, MD, FACS, presented her findings on the benefits of nomogram during a panel on “Breast Pathology for the Non-Pathologist” at the 18<sup>th</sup> annual Lynn Sage Breast Cancer Symposium in Chicago.<br />
Read More
The Crossroads of Precision Medicine and Treatment Decision Making in Breast Cancer
September 23rd 2016In an era of simultaneous increased evaluative testing in the United States and a rise in early-stage breast cancer diagnosis, it’s important that those facing treatment decisions for curable cancer understand the advances and advantages in precision medicine, explained Steven J. Katz, MD, MPH.
Read More